SEC Form 4 · accession 0001209191-17-029471
Axovant Sciences Ltd. · AXON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Atul Pande
Director
Period of report
Apr 28, 2017
Accepted (ET)
May 2, 2017 · 9:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636050
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $24.24 | Apr 28, 2017 | A | 27,000 | A | — | Apr 28, 2027 | Common Shares | 27,000 | 27,000 | D |
Explanation of responses
- F1100% of this option will vest one year after the date of grant. The option allows for early exercise, subject to the issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.
- F2Includes only options with the same termination date.
Remarks
Exhibit List - Exhibit 24 - Power of Attorney